Mandate

Vinge advises Cell Impact AB (publ) in connection with a directed share issue

Vinge has advised Cell Impact AB (publ) in connection with a directed share issue, whereby Cell Impact receives proceeds of SEK 175 million.

The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process. The purpose of the share issue is to finance Cell Impact’s continued path towards commercialization and expand the production capacity in the new factory in order to pave the way for expanded serial production.

Vinge’s team has consisted of Johan Larsson, Dain Hård Nevonen, Rikard Lindahl, Maria Dahlin-Kolvik, Joel Magnusson, Vilhelm Rondahl and Linnea Petersson.

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025